27 results on '"David B. Bharucha"'
Search Results
2. Design and Rationale of a Phase 2 Study of NeurOtoxin (Botulinum Toxin Type A) for the PreVention of Post-Operative Atrial Fibrillation - The NOVA Study
- Author
-
Mitchell F. Brin, Jonathan S. Steinberg, Anders Ahlsson, Nathan H. Waldron, Louis P. Perrault, Paul Dorian, Michael J. Mack, Lawrence M. Adams, William G. Ferguson, Stefano Benussi, David B. Bharucha, Jonathan P. Piccini, Peter R. Kowey, Marc Gillinov, and Carmelo A. Milano
- Subjects
Tachycardia ,medicine.medical_specialty ,Time Factors ,Botulinum Toxins ,Neurotoxins ,Placebo ,law.invention ,Type A ,Postoperative Complications ,law ,Atrial Fibrillation ,Clinical endpoint ,medicine ,Humans ,Botulinum Toxins, Type A ,Cardiac Surgical Procedures ,business.industry ,Atrial fibrillation ,medicine.disease ,Botulinum toxin ,Intensive care unit ,Cardiac surgery ,Anesthesia ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business ,Complication ,medicine.drug - Abstract
Background : Post-operative AF (POAF) is the most common complication following cardiac surgery, occurring in 30% to 60% of patients undergoing bypass and/or valve surgery. POAF is associated with longer intensive care unit/hospital stays, increased healthcare utilization, and increased morbidity and mortality. Injection of botulinum toxin type A into the epicardial fat pads resulted in reduction of AF in animal models, and in 2 clinical studies of cardiac surgery patients, without new safety observations. Methods : The objective of NOVA is to assess the use of AGN-151607 (botulinum toxin type A) for prevention of POAF in cardiac surgery patients. This randomized, multi-site, placebo-controlled trial will study one-time injections of AGN-151607 125 U (25 U / fat pad) and 250 U (50 U / fat pad) or placebo during cardiac surgery in ∼330 participants. Primary endpoint: % of patients with continuous AF ≥ 30 s. Secondary endpoints include several measures of AF frequency, duration, and burden. Additional endpoints include clinically important tachycardia during AF, time to AF termination, and healthcare utilization. Primary and secondary efficacy endpoints will be assessed using continuous ECG monitoring for 30 days following surgery. All patients will be followed for up to 1 year for safety. Conclusion : The NOVA Study will test the hypothesis that injections of AGN-151607 will reduce the incidence of POAF and associated resource utilization. If demonstrated to be safe and effective, the availability of a one-time therapy for the prevention of POAF would represent an important treatment option for patients undergoing cardiac surgery.
- Published
- 2022
3. Results of a curtailed randomized controlled trial, evaluating the efficacy and safety of azimilide in patients with implantable cardioverter-defibrillators: The SHIELD-2 trial
- Author
-
David B. Bharucha, Paul Dorian, Victoria M. Robinson, Kenneth W. Mahaffey, and Peter R. Kowey
- Subjects
Male ,Azimilide ,medicine.medical_specialty ,Electric Countershock ,030204 cardiovascular system & hematology ,Neutropenia ,Ventricular tachycardia ,Piperazines ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Double-Blind Method ,Randomized controlled trial ,law ,Internal medicine ,Odds Ratio ,medicine ,Humans ,Cardiac and Cardiovascular Systems ,030212 general & internal medicine ,Adverse effect ,Intensive care medicine ,Aged ,Proportional Hazards Models ,Heart Failure ,Kardiologi ,business.industry ,Hydantoins ,Stroke Volume ,Odds ratio ,Emergency department ,Middle Aged ,medicine.disease ,Defibrillators, Implantable ,Hospitalization ,Death, Sudden, Cardiac ,Cardiovascular Diseases ,Early Termination of Clinical Trials ,Ventricular Fibrillation ,Ventricular fibrillation ,Tachycardia, Ventricular ,Female ,Emergency Service, Hospital ,business ,Cardiology and Cardiovascular Medicine ,Anti-Arrhythmia Agents ,medicine.drug - Abstract
BACKGROUND: Frequent hospital attendances in patients with implantable cardioverter-defibrillators (ICDs) result in significant morbidity and health care costs. Current drugs to reduce ICD shocks and hospital visits have limited efficacy and considerable toxicity. We evaluated the efficacy and safety of azimilide, a novel oral class III antiarrhythmic, for use in ICD patients. METHODS: A total of 240 patients were enrolled in a prospective, randomized, double-blind, placebo-controlled trial to evaluate the effect of oral azimilide 75 mg daily in ICD patients with previously documented ventricular tachycardia or ventricular fibrillation, and a left ventricular ejection fraction ≤40%. The primary outcome metric was the adjudicated time-to-first unplanned cardiovascular (CV) hospitalization, or CV emergency department (ED) visit, or CV death. The trial was prematurely discontinued due to withdrawal of study sponsorship. RESULTS: Azimilide demonstrated numerical but statistically nonsignificant reductions in the primary composite outcome (odds ratio [OR] 0.79, 95% CI 0.44-1.44), unplanned CV hospitalizations (OR 0.75, 95% CI 0.41-1.38), ED visits (OR 0.68, 95% CI 0.35-1.31), and all-cause shocks (OR 0.58, 95% CI 0.32-1.05). The incidence of adverse events was lower in the azimilide group. Neutropenia was not observed (absolute neutrophil count Carina Blomström-Lundqvist ingår i SHIELD-2 Investigators.
- Published
- 2017
- Full Text
- View/download PDF
4. Efficacy of nebivolol-valsartan single-pill combination in obese and nonobese patients with hypertension
- Author
-
Madhuja Mallick, William G. Ferguson, Mehul D. Patel, David B. Bharucha, Christian W. Mende, and Thomas D. Giles
- Subjects
Male ,obesity ,Angiotensin receptor ,Endocrinology, Diabetes and Metabolism ,Blood Pressure ,030204 cardiovascular system & hematology ,Biomarkers, Pharmacological ,Body Mass Index ,Nebivolol ,chemistry.chemical_compound ,0302 clinical medicine ,Heart Rate ,Risk Factors ,Medicine ,030212 general & internal medicine ,Aldosterone ,Blood Pressure Monitoring, Ambulatory ,Middle Aged ,Treatment Outcome ,Valsartan ,Adrenergic beta-1 Receptor Agonists ,Drug Therapy, Combination ,Female ,Cardiology and Cardiovascular Medicine ,Glomerular Filtration Rate ,medicine.drug ,Adult ,medicine.medical_specialty ,hypertension ,Ambulatory blood pressure ,Urology ,Renal function ,Therapetics ,Placebo ,valsartan ,single‐pill combination ,03 medical and health sciences ,Internal medicine ,Internal Medicine ,Humans ,Antihypertensive Agents ,Original Paper ,business.industry ,Endocrinology ,Blood pressure ,chemistry ,business ,Angiotensin II Type 1 Receptor Blockers - Abstract
Antihypertensive efficacy of single‐pill combinations (SPCs) consisting of a β1‐selective adrenergic blocker with vasodilatory properties via β3‐agonism (nebivolol) and an angiotensin II receptor blocker (valsartan) was demonstrated in an 8‐week phase 3 trial (NCT01508026). In this post hoc analysis, seated blood pressure, heart rate, 24‐hour ambulatory blood pressure monitoring, plasma aldosterone, estimated glomerular filtration rate, and safety measures were assessed in obese (body mass index >32 kg/m2; n=1823) and nonobese (body mass index
- Published
- 2017
5. Correlations of plasma renin activity and aldosterone concentration with ambulatory blood pressure responses to nebivolol and valsartan, alone and in combination, in hypertension
- Author
-
Thomas D. Giles, George Bakris, Suzanne Oparil, Michael A. Weber, Huiling Li, Madhuja Mallick, David B. Bharucha, ChunLin Chen, William G. Ferguson, John Sorin, Matthew Davis, Joesph Izzo, Nabile Andrawis, Alyn Anderson, Rogelio Bardinas-Rodriguez, Douglas Young, Andrew Schreiber, Cristian Breton, Duane Harris, Phillip LaStella, Ramon Castello, Susan Hole, Joesph Lillo, Luis Carlos Quintero, Carlos Montenegro, Jeffrey Rosen, Farid Marquez, Fredric Adler, Sady Alpizar, James Andersen, Corey Anderson, Graciela Calatayud, Kevin Cannon, Deanna Cheung, Rafel Chiong, Lisa Cohen, Harry Collins, Michael Dao, Cara H. Dawson, Donna DeSantis, Shelly Dunmyer, Sherif El-Harazi, Cecil M. Farrington, David Ferrera, Gregory S. Funk, Gregory Gottschlich, Terence T. Hart, Marvin Kalafer, Dean Kereiakes, Gigi Lefebvre, Aristolis Laliotis, Peter Mattar, Michael McCartney, Diane McConnehey, Curtis Mello, Joel Neutel, Deborah A. Burke, James Pritchard, George Raad, Bruce Rankin, John 'Chip' H. Reed, Erich Schramm, Howard Schwartz, Nathan Segall, James Shoemaker, Vakas Sial, Teresa Sligh, William Smith, Richard Stewart, Dan Streja, Danny Sugimoto, Alexander White, Hayes Williams, William Abraham, Azazuddin Ahmed, Richard Beasley, Daniel Gruener, Connie Hsu, Ryan Klein, Allen Soo, Charles P. Andrews, Clinton Corder, Donald Hurley, Elizabeth Bretton, Richard Martinez, David Morin, Miguel Trevino, Samir Arora, Curtis Scott Horn, Charles Lovell, Thomas Nussdorfer, Robert Weiss, Harold Bays, Jackson Rhudy, Edwardo Almaguer, Joseph H. Woolley, Vicki Miller, Jaynier Moya-Hechevarria, Henry Punzi, Addison Taylor, Jonathan Wilson, Arnold Alper, Patricia Buchanan, Richard Dobrusin, Alan Forker, Razmig Krumian, Samuel F. Oberstein, Andrew Lewin, Mary Bella Natividad, Armando Segui, Wayne Harper, Andrea Lawless, Lawrence S. Levinson, Shaukat Shah, Loray Blair-Britt, Patrick Carmichael, Nathaniel Winer, David Grant, Kyle Rickner, Absalom Tilley, Linda Harper, Stephen Maddock, Joseph A. Boscia, Yekaterina Khronusova, Larry D. Reed, and Chandar Abboy
- Subjects
Male ,Angiotensin receptor ,medicine.medical_specialty ,Ambulatory blood pressure ,Maximum Tolerated Dose ,Urology ,Diastole ,Risk Assessment ,Severity of Illness Index ,Plasma renin activity ,Nebivolol ,Renin-Angiotensin System ,Vasodilatory beta-blocker ,chemistry.chemical_compound ,Double-Blind Method ,Internal medicine ,Renin ,Renin–angiotensin system ,ABPM ,Internal Medicine ,Humans ,Medicine ,Aldosterone ,Dose-Response Relationship, Drug ,business.industry ,Patient Selection ,biomarkers ,Blood Pressure Monitoring, Ambulatory ,angiotensin II receptor blocker ,Treatment Outcome ,Endocrinology ,chemistry ,Valsartan ,Hypertension ,Drug Therapy, Combination ,Female ,Cardiology and Cardiovascular Medicine ,business ,Follow-Up Studies ,medicine.drug - Abstract
After demonstration of the antihypertensive efficacy of the combination of the beta-blocker nebivolol and the angiotensin receptor blocker valsartan in an 8-week, randomized, placebo-controlled trial (N = 4161), we now report the effects of this treatment on the renin-angiotensin-aldosterone system in a substudy (n = 805). Plasma renin activity increased with valsartan (54%–73%) and decreased with nebivolol (51%–65%) and the combination treatment (17%–39%). Plasma aldosterone decreased with individual treatments (valsartan, 11%–22%; nebivolol, 20%–26%), with the largest reduction (35%) observed with maximum combination dose (20 mg nebivolol/320 mg valsartan). Baseline ln(plasma renin activity) correlated with the 8-week reductions in 24-hour systolic and diastolic BP following treatments with the combination (all doses combined, P = .003 and P
- Published
- 2015
6. Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study
- Author
-
Thomas D, Giles, Michael A, Weber, Jan, Basile, Alan H, Gradman, David B, Bharucha, Wei, Chen, Manoj, Pattathil, and Chandar, Abboy
- Subjects
Adult ,Male ,Adrenergic beta-Antagonists ,Fixed-dose combination ,Tetrazoles ,Blood Pressure ,Pharmacology ,Placebo ,Drug Administration Schedule ,Nebivolol ,law.invention ,Young Adult ,Double-Blind Method ,Randomized controlled trial ,law ,Humans ,Medicine ,Benzopyrans ,Adverse effect ,Antihypertensive Agents ,Aged ,Intention-to-treat analysis ,Dose-Response Relationship, Drug ,business.industry ,Valine ,General Medicine ,Middle Aged ,Drug Combinations ,Treatment Outcome ,Blood pressure ,Valsartan ,Ethanolamines ,Anesthesia ,Hypertension ,Female ,business ,Angiotensin II Type 1 Receptor Blockers ,medicine.drug - Abstract
The fixed-dose combination of any two antihypertensive drugs from different drug classes is typically more effective in reducing blood pressure than a dose increase of component monotherapy. We assessed the efficacy and safety of a fixed-dose combination of a vasodilating β blocker (nebivolol) and an angiotensin II receptor blocker (valsartan) in adults with hypertension.We did an 8-week, phase 3, multicentre, randomised, double-blind, placebo-controlled, parallel-group trial at 401 US sites. Participants (age ≥18 years) with hypertension but with blood pressure less than 180/110 mm Hg were randomly assigned (2:2:2:2:2:2:2:1) by a 24-h interactive web response system in blocks of 15 to 4 weeks of double-blind treatment with nebivolol and valsartan fixed-dose combination (5 and 80 mg/day, 5 and 160 mg/day, or 10 and 160 mg/day), nebivolol (5 mg/day or 20 mg/day), valsartan (80 mg/day or 160 mg/day), or placebo. Doses were doubled in weeks 5-8; results are reported according to the final dose. Participants and research staff were masked to treatment allocation. The primary and key secondary endpoints were changes from baseline to week 8 in diastolic and systolic blood pressure, respectively. The primary statistical comparison was between the highest fixed-dose combination dose and the highest monotherapy doses; lower doses were then compared if this comparison was positive (Hochberg method for multiple testing). Efficacy analyses were by intention to treat. Safety assessments included monitoring of adverse events. Continuous efficacy parameters were analysed using an ANCOVA model; binary outcomes were analysed using a logistic regression model. This study is registered with ClinicalTrials.gov, NCT01508026.Between Jan 6, 2012, and March 15, 2013, 4161 patients were randomly assigned (277 to placebo and 554-555 to each active comparator group), 4118 of whom were included in the primary analysis. At week 8, the fixed-dose combination 20 and 320 mg/day group had significantly greater reductions in diastolic blood pressure from baseline than both nebivolol 40 mg/day (least-squares mean difference -1·2 mm Hg, 95% CI -2·3 to -0·1; p=0·030) and valsartan 320 mg/day (-4·4 mm Hg, -5·4 to -3·3; p0·0001); all other comparisons were also significant, favouring the fixed-dose combinations (all p0·0001). All systolic blood pressure comparisons were also significant (all p0·01). At least one treatment-emergent adverse event was experienced by 30-36% of participants in each group.Nebivolol and valsartan fixed-dose combination is an effective and well-tolerated treatment option for patients with hypertension.Forest Research Institute.
- Published
- 2014
7. Refinement of the Magnetic Resonance Diffusion-Perfusion Mismatch Concept for Thrombolytic Patient Selection
- Author
-
Steven Warach, Annika Lindsten, Anthony J. Furlan, Max Wintermark, Jochen B. Fiebach, Howard A. Rowley, Salvador Pedraza, Yasir Al-Rawi, David B. Bharucha, and Jamal Smyej
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,medicine.medical_treatment ,law.invention ,Lesion ,Plasminogen Activators ,Young Adult ,Fibrinolytic Agents ,Randomized controlled trial ,law ,Internal medicine ,Odds Ratio ,medicine ,Humans ,Desmoteplase ,Thrombolytic Therapy ,Stroke ,Aged ,Aged, 80 and over ,Advanced and Specialized Nursing ,medicine.diagnostic_test ,business.industry ,Penumbra ,Magnetic resonance imaging ,Thrombolysis ,Odds ratio ,Middle Aged ,medicine.disease ,Magnetic Resonance Imaging ,Surgery ,Treatment Outcome ,Sample Size ,Reperfusion ,Cardiology ,Female ,Neurology (clinical) ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business - Abstract
Background and Purpose— The DIAS-2 study was the only large, randomized, intravenous, thrombolytic trial that selected patients based on the presence of ischemic penumbra. However, DIAS-2 did not confirm the positive findings of the smaller DEDAS and DIAS trials, which also used penumbral selection. Therefore, a reevaluation of the penumbra selection strategy is warranted. Methods— In post hoc analyses we assessed the relationships of magnetic resonance imaging–measured lesion volumes with clinical measures in DIAS-2, and the relationships of the presence and size of the diffusion-perfusion mismatch with the clinical effect of desmoteplase in DIAS-2 and in pooled data from DIAS, DEDAS, and DIAS-2. Results— In DIAS-2, lesion volumes correlated with National Institutes of Health Stroke Scale (NIHSS) at both baseline and final time points ( P P =0.004). In the pooled analysis, desmoteplase was associated with 47% clinical response rate (n=143) vs 34% in placebo (n=73; P =0.08). For both the pooled sample and for DIAS-2, increasing the minimum baseline mismatch volume (MMV) for inclusion increased the desmoteplase effect size. The odds ratio for good clinical response between desmoteplase and placebo treatment was 2.83 (95% confidence interval, 1.16–6.94; P =0.023) for MMV >60 mL. Increasing the minimum NIHSS score for inclusion did not affect treatment effect size. Conclusions— Pooled across all desmoteplase trials, desmoteplase appears beneficial in patients with large MMV and ineffective in patients with small MMV. These results support a modified diffusion-perfusion mismatch hypothesis for patient selection in later time-window thrombolytic trials. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique Identifiers: NCT00638781, NCT00638248, NCT00111852.
- Published
- 2012
8. Left Ventricular Hypertrophy Decreases Slowly but Not Rapidly Activating Delayed Rectifier Potassium Currents of Epicardial and Endocardial Myocytes in Rabbits
- Author
-
Ying Wu, David B. Bharucha, Xiaoping Xu, Peter R. Kowey, Joseph J. Salata, Seth J. Rials, Tengxian Liu, and Roger A. Marinchak
- Subjects
Male ,medicine.medical_specialty ,Potassium Channels ,Action Potentials ,Left ventricular hypertrophy ,Muscle hypertrophy ,Physiology (medical) ,Internal medicine ,Animals ,Medicine ,Repolarization ,Myocyte ,Ion channel ,Endocardium ,Lagomorpha ,biology ,business.industry ,Myocardium ,biology.organism_classification ,medicine.disease ,Electrophysiology ,Endocrinology ,Potassium Channels, Voltage-Gated ,Cardiology ,Hypertrophy, Left Ventricular ,Rabbits ,Cardiology and Cardiovascular Medicine ,business ,Pericardium ,Delayed Rectifier Potassium Channels - Abstract
Background —Delayed rectifier K + currents are critical to action potential (AP) repolarization. The present study examines the effects of left ventricular hypertrophy (LVH) on delayed rectifier K + currents and their contribution to AP repolarization in both epicardial (Epi) and endocardial (Endo) myocytes. Methods and Results —LVH was induced in rabbits by a 1-kidney removal, 1-kidney vascular clamping method. Slowly ( I Ks ) and rapidly ( I Kr ) activating delayed rectifier K + currents were recorded by the whole-cell patch-clamp technique, and APs were recorded by the microelectrode technique. In normal rabbit left ventricular myocytes, I Ks densities were larger in Epi than in Endo (1.1±0.1 versus 0.43±0.07 pA/pF), whereas I Kr density was similar between Epi and Endo (0.31±0.05 versus 0.36±0.07 pA/pF) at 20 mV. LVH reduced I Ks density to a similar extent (≈40%) in both Epi and Endo but had no significant effect on I Kr in either Epi or Endo. Consequently, I Kr was expected to contribute more to AP repolarization in LVH than in control. This was confirmed by specific I Kr block with dofetilide, which prolonged AP significantly more in LVH than in control (31±3% versus 18±2% in Epi; 53±6% versus 32±4% in Endo at 2 Hz). In contrast, L-768,673 (a specific I Ks blocker) prolonged AP less in LVH than in control. The very small I Ks density in Endo with LVH is consistent with the greater incidence of early afterdepolarizations induced in this region by dofetilide. Conclusions —LVH induces a decrease in I Ks density and increases the propensity to develop early afterdepolarizations, especially in Endo.
- Published
- 2001
9. Atrial fibrillation
- Author
-
Peter R. Kowey, Roger A. Marinchak, Seth J. Rials, and David B. Bharucha
- Subjects
medicine.medical_specialty ,business.industry ,Atrial fibrillation ,macromolecular substances ,medicine.disease ,Asymptomatic ,Clinical investigation ,cardiovascular system ,medicine ,cardiovascular diseases ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,Intensive care medicine ,business ,Stroke - Abstract
Atrial fibrillation will present the most significant arrhythmia management challenge for clinicians in the new millennium, particularly as the percentage of elderly patients and longevity increase worldwide. The clinical manifestations of the arrhythmia are wide ranging: paroxysmal to permanent modes of occurrence and asymptomatic to severely symptomatic presentations. Perhaps most important, the major risks of atrial fibrillation are stroke and death. Current therapies remain heavily focused on pharma-cologic efforts to reduce the severity of primary symptoms and to prevent stroke and other thromboembolic complications by means of anticoagulation. It has not yet been proven that prevention of atrial fibrillation will prolong survival, however. Nonphar-macologic therapies remain under intense basic and clinical investigation as promising means to improve outcome further for patients suffering from atrial fibrillation.
- Published
- 2000
10. Intravenous antiarrhythmic therapy in the acute control of in-hospital destabilizing ventricular tachycardia and fibrillation
- Author
-
Peter R. Kowey, Roger A. Marinchak, Seth J. Rials, and David B. Bharucha
- Subjects
medicine.medical_specialty ,Heart disease ,medicine.medical_treatment ,Amiodarone ,Infarction ,Antiarrhythmic agent ,Ventricular tachycardia ,Drug Administration Schedule ,Internal medicine ,medicine ,Humans ,cardiovascular diseases ,Infusions, Intravenous ,Fibrillation ,Dose-Response Relationship, Drug ,business.industry ,Hemodynamics ,medicine.disease ,Hospitalization ,Anesthesia ,Heart failure ,Ventricular Fibrillation ,Ventricular fibrillation ,Tachycardia, Ventricular ,cardiovascular system ,Cardiology ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business ,Anti-Arrhythmia Agents ,medicine.drug - Abstract
Ventricular tachycardia, which causes hemodynamic instability, and ventricular fibrillation do not occur frequently in any hospital. However, they usually occur in patients who have severe underlying cardiovascular disease such as myocardial ischemia/infarction or congestive heart failure, and they are associated with high mortality. Most of those deaths are due to an intractable arrhythmia, not suppressible with even the most potent antiarrhythmic drugs. Fortunately, during the last few years, our ability to suppress highly lethal ventricular arrhythmia has been enhanced by the approval of intravenous amiodarone. When used in appropriate patient populations, intravenous amiodarone has been successful in suppressing the most malignant arrhythmia, thus permitting aggressive and successful treatment of severe underlying cardiac conditions. This article reviews data on the use of parenteral antiarrhythmic drugs for the control of ventricular arrhythmia in patients in hospital, and will attempt to provide some guidance as to how these antiarrhythmic drugs may be used in specific patient populations to maximize their efficacy and safety. We will also make recommendations on the sequence of therapy for specific arrhythmias to optimize the chances of patient survival.
- Published
- 1999
11. The effects of nebivolol-valsartan single-pill combination in obese and non-obese individuals with hypertension
- Author
-
Christian W. Mende, Madhuja Mallick, William G. Ferguson, Thomas D. Giles, Mehul Patel, and David B. Bharucha
- Subjects
Single pill combination ,medicine.medical_specialty ,Non obese ,business.industry ,Internal medicine ,Internal Medicine ,medicine ,Cardiology ,Cardiology and Cardiovascular Medicine ,business ,NEBIVOLOL/VALSARTAN - Published
- 2015
12. Atrial fibrillation trials: will they teach us what we need to know?
- Author
-
Peter R. Kowey, Seth J. Rials, David B. Bharucha, Susan Heaney, and Roger A. Marinchak
- Subjects
Research design ,medicine.medical_specialty ,Nonpharmacologic interventions ,Defibrillation ,medicine.medical_treatment ,Electric Countershock ,Need to know ,Internal medicine ,Atrial Fibrillation ,medicine ,Humans ,Sinus rhythm ,Clinical Trials as Topic ,business.industry ,Cardiac Pacing, Artificial ,Atrial fibrillation ,medicine.disease ,Cardiac surgery ,Atrial Flutter ,Research Design ,cardiovascular system ,Cardiology ,Cardiology and Cardiovascular Medicine ,business ,Anti-Arrhythmia Agents ,Atrial flutter - Abstract
Atrial fibrillation (AF) has captured the imagination of clinical investigators who have initiated trials to examine several aspects of this multifaceted arrhythmia. We will review the protocol designs of ongoing trials that are examining the relative value of rhythm versus rate control, new methods for pharmacologic restoration and maintenance of sinus rhythm (including prophylaxis after cardiac surgery), and nonpharmacologic interventions such as pacing and atrial defibrillation. We antic ipate that the results of these studies will have a major impact on the care of patients with AF in the new millennium.
- Published
- 1998
13. [Untitled]
- Author
-
Seth J. Rials, Roger A. Marinchak, Peter R. Kowey, and David B. Bharucha
- Subjects
medicine.medical_specialty ,business.industry ,medicine ,Cardiology and Cardiovascular Medicine ,Intensive care medicine ,business - Published
- 1998
14. Pharmacologic and Pharmacokinetic Profile of Class III Antiarrhythmic Drugs
- Author
-
Seth J. Rials, David B. Bharucha, Peter R. Kowey, and Roger A. Marinchak
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,Ibutilide ,Amiodarone ,Dofetilide ,Pharmacology ,Antiarrhythmic agent ,Pharmacokinetics ,Internal medicine ,Phenethylamines ,Cardiac conduction ,Humans ,Medicine ,Sulfonamides ,business.industry ,Bretylium Compounds ,Sotalol ,Arrhythmias, Cardiac ,Cardiac Arrhythmia Suppression Trial ,Anesthesia ,Cardiology ,Cardiology and Cardiovascular Medicine ,business ,Anti-Arrhythmia Agents ,medicine.drug - Abstract
Cardiac arrhythmias frequently respond only to drugs that have as their predominant electrophysiologic effect the prolongation of repolarization and refractoriness. According to the Singh–Vaughan Williams classification, these drugs are known as class III agents. In the last few years, interest has increased in the development of class III antiarrhythmic drugs as alternatives to sodium channel blocking agents, which mainly affect cardiac conduction. Much of this interest results from a perceived danger of using drugs with sodium channel blocking properties, particularly in patients with ischemic heart disease, based on the results of the Cardiac Arrhythmia Suppression Trial (CAST) and several other trials. This article is a review of the pharmacology, including the pharmacokinetics and pharmacodynamics, of the most commonly used and investigated class III antiarrhythmic drugs. As will be seen from the discussion, each of these drugs has novel pharmacology that makes it applicable in specific clinical situations. Their putative effects on various arrhythmogenic mechanisms and their efficacy in treating specific target arrhythmias will be addressed.
- Published
- 1997
15. The Effects of Nebivolol-Valsartan Single-Pill Combinations in Reducing Blood Pressure in Patients with Stage I or II Hypertension
- Author
-
Michael A. Weber, Mehul Patel, George L. Bakris, L. Xie, David B. Bharucha, and William B. White
- Subjects
medicine.medical_specialty ,business.industry ,030204 cardiovascular system & hematology ,030226 pharmacology & pharmacy ,03 medical and health sciences ,0302 clinical medicine ,Blood pressure ,Internal medicine ,Pill ,Internal Medicine ,Cardiology ,Medicine ,In patient ,Cardiology and Cardiovascular Medicine ,business ,NEBIVOLOL/VALSARTAN - Published
- 2016
16. Abstract 2600: Refinement of the MR Diffusion-perfusion Mismatch Concept for Thrombolytic Patient Selection: Insights from the Desmoteplase In Acute Stroke Trials
- Author
-
Steven Warach, Yasir Al-Rawi, Anthony J Furlan, Jochen B Fiebach, Max Wintermark, Annika Lindsten, Jamal Smyej, David B Bharucha, Salvador Pedraza, and Howard A Rowley
- Subjects
Advanced and Specialized Nursing ,Neurology (clinical) ,Cardiology and Cardiovascular Medicine - Abstract
The DIAS-2 study was the only large, randomized intravenous thrombolytic trial that selected patients based on the presence of ischemic penumbra. However, DIAS-2 did not confirm the positive findings of the smaller DEDAS and DIAS trials, which also used penumbral selection. Therefore a reevaluation of the penumbra selection strategy is warranted. In post-hoc analyses we assessed the relationships of MRI-measured lesion volumes to clinical measures in DIAS-2, and the relationships of the presence and size of the diffusion-perfusion mismatch to the clinical effect of desmoteplase in DIAS-2 (MRI-selected patients) and in pooled data from MRI-selected 90- and 125-μg/kg dose groups in DIAS, DEDAS, and DIAS-2. In DIAS-2, lesion volumes correlated with NIHSS at both baseline and final time points (P60 mL baseline mismatch subgroups (P=0.083). The odds ratio for good clinical response between desmoteplase and placebo treatment was 2.83 (95% CI, 1.16-6.94, P=0.023) for a MMV >60 mL. Increasing the minimum NIHSS for inclusion did not affect treatment effect size. Pooled across all desmoteplase trials, penumbral selection by MRI diffusion-perfusion mismatch favored desmoteplase clinical benefit, especially for larger MMV. Based on these results, a three-fold reduction in future trial sample size requirements would be achieved using a criterion of baseline MMV >60 mL over any visible mismatch. These results support a modified diffusion-perfusion mismatch hypothesis for patient selection in later-time-window thrombolytic trials.
- Published
- 2012
17. Contributors
- Author
-
Raushan Abdula, Michael J. Ackerman, Masood Akhtar, Rishi Anand, Kelley Anderson, Charles Antzelevitch, Angelo Auricchio, Nitish Badhwar, Shane Bailey, Conor D. Barrett, Antonio Bayes de Luna, Paul Belk, David G. Benditt, Begoña Benito, Matthew T. Bennett, Saroja Bharati, David B. Bharucha, William J. Bonney, Neil E. Bowles, Penelope A. Boyden, Babak Bozorgnia, Günter Breithardt, Josep Brugada, Pedro Brugada, Ramon Brugada, Thomas Adam Burkart, J. David Burkhardt, Hugh Calkins, A. John Camm, Franco Cecchi, Marina Cerrone, Nipon Chattipakorn, Shih-Ann Chen, Alexandru B. Chicos, Indrajit Choudhuri, Sebastien Clauss, Jamie Beth Conti, Jonathan M. Cordeiro, Bettina F. Cuneo, Shane R. Cunha, Anne B. Curtis, Michael J. Cutler, Iwona Cygankiewicz, Ralph J. Damiano, James P. Daubert, Jean-Claude Daubert, D. Wyn Davies, Prakash Deedwania, Paul J. DeGroot, Nicolas Derval, Luigi Di Biase, Timm-Michael Dickfeld, Dobromir Dobrev, Michael Domanski, Paul Dorian, Hiten Doshi, Heather S. Duffy, Lars Eckardt, David Eisner, Kenneth A. Ellenbogen, Perry M. Elliott, Nabil El-Sherif, Sabine Ernst, N.A. Mark Estes, Michael D. Ezekowitz, John D. Fisher, Glenn I. Fishman, Andrei Forclaz, G. Joseph Gallinghouse, Ann C. Garlitski, Edward P. Gerstenfeld, Jaswinder Gill, Anne M. Gillis, Jason A. Goebel, Michael R. Gold, Pamela S.N. Goldman, Nora Goldschlager, Lorne J. Gula, Michel Haïssaguerre, John-John Hamel, Donald D. Hegland, Douglas Hettrick, Siew Yen Ho, Mélèze Hocini, Munther K. Homoud, Rodney Horton, Jose F. Huizar, Thomas J. Hund, Raymond E. Ideker, Ramesh Iyer, Kevin P. Jackson, Amir Jadidi, Pierre Jaïs, José Jalife, Michiel Janse, Luc Jordaens, Werner Jung, Stefan Kääb, Alan H. Kadish, Jonathan M. Kalman, Bharat K. Kantharia, Karoly Kaszala, Demosthenes G. Katritsis, Elizabeth S. Kaufman, Susan S. Kim, Senthil Kirubakaran, George J. Klein, Helmut Klein, Sébastien Knecht, Bradley Knight, Paul Knops, Jacob S. Koruth, Peter R. Kowey, Andrew D. Krahn, Andrew Krumerman, Vikas Kuriachan, Fred Kusumoto, Joel A. Lardizabal, Chu-Pak Lau, David H. Lau, Ralph Lazzara, Anson M. Lee, Peter Leong-Sit, Samuel Levy, Thorsten Lewalter, Hua Li, Bruce D. Lindsay, Nick W.F. Linton, Nandini Madan, Yousuf Mahomed, Louisa Malcolme-Lawes, Frank Marchlinski, Barry J. Maron, Ruth McBride, William J. McKenna, Rahul Mehra, Anjlee M. Mehta, John M. Miller, L. Brent Mitchell, Peter J. Mohler, Carlos A. Morillo, Alison R. Muir, Shisuke Myazaki, Robert J. Myerburg, Gerald V. Naccarelli, Rangadham Nagarakanti, Navin C. Nanda, Carlo Napolitano, Andrea Natale, Stanley Nattel, Isabelle Nault, Sami F. Noujaim, Iacopo Olivotto, Heyder Omran, Luigi Padeletti, Richard L. Page, David S. Park, Mark Preminger, Silvia G. Priori, Kara J. Quan, Satish R. Raj, John Rawlins, Shakeeb Razak, Shantanu Reddy, Vivek Y. Reddy, Robert W. Rho, Larry A. Rhodes, Abel Rivero, Melissa Robinson, Dionyssios Robotis, Dan M. Roden, Michael J. Root, Michael R. Rosen, David Rosenbaum, Jeremy Ruskin, Frédéric Sacher, Scott Sakaguchi, Sanjeev Saksena, Javier Sanchez, Pasquale Santageli, Irina Savelieva, Mark H. Schoenfeld, Peter J. Schwartz, Robert Schweikert, Oliver R. Segal, Dipen Shah, Maully Shah, Arjun Sharma, Sanjay Sharma, Robert S. Sheldon, Kaori Shinagawa, Bramah N. Singh, Steven Singh, Chung-Wah Siu, Nicholas D. Skadsberg, Allan C. Skanes, April Slee, Jasbir Sra, Gerhard Steinbeck, David Steinhaus, William G. Stevenson, Janette F. Strasburger, Raymond W. Sy, Andrew W. Teh, David J. Tester, Gordon Tomaselli, Jeffrey A. Towbin, Jacques Turgeon, Gioia Turitto, Wendy Tzou, J. Gert van Dijk, George F. Van Hare, Nathan Van Houzen, Matteo Vatta, Vasanth Vedantham, Victoria L. Vetter, Rochus K. Voeller, Galen Wagner, Reza Wakili, Mariah L. Walker, Paul J. Wang, Andrew L. Wit, Matthew Wright, Raymond Yee, Jason D. Zagrodsky, Wojciech Zareba, Stephan Zellerhoff, and Paul Ziegler
- Published
- 2012
18. Postoperative Arrhythmias After Cardiac Surgery
- Author
-
David B. Bharucha, Babak Bozorgnia, and Peter R. Kowey
- Published
- 2012
19. Lack of kringle 2 domain and high fibrin specificity differentiate the novel plasminogen activator desmoteplase from rt‐PA
- Author
-
David B Bharucha, Michael K Pugsley, Karl-Uwe Petersen, and Mariola Soehngen
- Subjects
biology ,business.industry ,Pharmacology ,Biochemistry ,Fibrin ,Genetics ,biology.protein ,Medicine ,Desmoteplase ,Symptom onset ,Recombinant tissue plasminogen activator ,business ,Molecular Biology ,Plasminogen activator ,Acute ischemic stroke ,Biotechnology - Abstract
Thrombolytic therapy with recombinant tissue plasminogen activator (rt-PA) is effective in treating acute ischemic stroke (AIS) within the first 3 hours after symptom onset. Desmoteplase, or rDSPAα...
- Published
- 2007
20. Efficacy and tolerability of a nebivolol-valsartan single-pill combination by sex in individuals with hypertension
- Author
-
Mehul Patel, Madhuja Mallick, Thomas D. Giles, Suzanne Oparil, David B. Bharucha, and William G. Ferguson
- Subjects
Single pill combination ,Tolerability ,business.industry ,Internal Medicine ,Medicine ,Pharmacology ,Cardiology and Cardiovascular Medicine ,business ,NEBIVOLOL/VALSARTAN - Published
- 2015
21. Postoperative Arrhythmias After Cardiac Surgery
- Author
-
David B. Bharucha and Peter R. Kowey
- Subjects
medicine.medical_specialty ,business.industry ,Internal medicine ,medicine ,Cardiology ,business ,Cardiac surgery - Published
- 2005
22. Plasma renin activity and aldosterone levels in patients with hypertension receiving fixed-dose combination of nebivolol and valsartan: substudy of a phase 3 randomized trial
- Author
-
Thomas D. Giles, Chun Lin Chen, Michael A. Weber, David B. Bharucha, George L. Bakris, Suzanne Oparil, William G. Ferguson, and Wei Chen
- Subjects
medicine.medical_specialty ,business.industry ,Fixed-dose combination ,Urology ,Aldosterone levels ,Plasma renin activity ,Nebivolol ,law.invention ,Valsartan ,Randomized controlled trial ,law ,Internal Medicine ,medicine ,In patient ,Cardiology and Cardiovascular Medicine ,business ,medicine.drug - Published
- 2014
23. Fixed-dose combination of nebivolol and valsartan in patients with stage 1 or 2 hypertension: ABPM substudy of a phase 3 randomized trial
- Author
-
Suzanne Oparil, William G. Ferguson, Michael A. Weber, David B. Bharucha, Chun Lin Chen, George L. Bakris, Thomas D. Giles, and Wei Chen
- Subjects
medicine.medical_specialty ,business.industry ,Fixed-dose combination ,Urology ,Nebivolol ,law.invention ,Valsartan ,Randomized controlled trial ,law ,Internal Medicine ,medicine ,In patient ,Stage (cooking) ,Cardiology and Cardiovascular Medicine ,business ,medicine.drug - Published
- 2014
24. Classification and pharmacology of antiarrhythmic drugs
- Author
-
Seth J. Rials, David B. Bharucha, Roger A. Marinchak, and Peter R. Kowey
- Subjects
Drug ,Proarrhythmia ,Bradycardia ,Dose-Response Relationship, Drug ,business.industry ,media_common.quotation_subject ,Cardiac arrhythmia ,Arrhythmias, Cardiac ,Disease ,Pharmacology ,medicine.disease ,Sensitivity and Specificity ,cardiovascular system ,medicine ,Humans ,Pharmacologic therapy ,Drug Interactions ,cardiovascular diseases ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business ,Anti-Arrhythmia Agents ,media_common ,Aged - Abstract
Despite the emergence of several forms of nonpharmacologic therapy for cardiac arrhythmias, antiarrhythmic drugs continue to play an important role in the management of patients with this common clinical problem. The key to the proper use of antiarrhythmic drugs is a thorough knowledge of their mode of action and pharmacology. The pharmacology of antiarrhythmic drugs is particularly important because patients with cardiac arrhythmias frequently have multiorgan disease, which may influence the metabolism and elimination of antiarrhythmic drugs. The accumulation of toxic amounts of these agents can lead to dire effects including, but not limited to, ventricular proarrhythmia and malignant bradycardia. The goals of pharmacologic therapy of cardiac arrhythmia are to provide the maximum benefit in terms of arrhythmia suppression while maintaining patient safety. To accomplish these goals, a knowledge of the pharmacology of several antiarrhythmic drugs is mandatory.
- Published
- 2000
25. Management and prevention of atrial fibrillation after cardiovascular surgery
- Author
-
Peter R. Kowey and David B. Bharucha
- Subjects
medicine.medical_specialty ,Heart disease ,medicine.medical_treatment ,Adrenergic beta-Antagonists ,Antiarrhythmic agent ,Cardioversion ,Postoperative Complications ,Risk Factors ,Internal medicine ,Atrial Fibrillation ,medicine ,Humans ,cardiovascular diseases ,Derivation ,Cardiac Surgical Procedures ,Modalities ,business.industry ,Sotalol ,Cardiac Pacing, Artificial ,Atrial fibrillation ,medicine.disease ,Prognosis ,Surgery ,Cardiac surgery ,cardiovascular system ,Cardiology ,Cardiology and Cardiovascular Medicine ,Complication ,business ,Anti-Arrhythmia Agents - Abstract
Atrial arrhythmias occur frequently after cardiac surgery. This article discusses the incidence of postoperative atrial arrhythmia as well as its prognosis, potential mechanisms of pathogenesis, and management. Prophylactic therapy for postoperative atrial arrhythmia is recommended because of the frequency of occurrence and the ease with which therapies can often be implemented. Treatments with pharmacologic and nonpharmacologic modalities are described. Management strategies for atrial arrhythmias that occur postoperatively, including pharmacologic and nonpharmacologic measures as well as anticoagulation recommendations, are discussed.
- Published
- 2000
26. P2-119
- Author
-
Nathan E. Goldstein, Joseph A. Gomes, Tracey Munson, Manish Undavia, Magdalena Singson, Davendra Mehta, Pilar Cohen, David B. Bharucha, Divaya Bhutani, and Kamoltip Sinthawanarong
- Subjects
medicine.medical_specialty ,Quality of life (healthcare) ,Recall ,business.industry ,Physiology (medical) ,medicine.medical_treatment ,Anxiety depression ,medicine ,Physical therapy ,Cardiology and Cardiovascular Medicine ,Implantable cardioverter-defibrillator ,business - Published
- 2006
27. Clinical utility of head-up tilt table testing in very elderly patients
- Author
-
Truong D. Duong, Davendra Mehta, David J. Harnick, J. Anthony Gomes, Sunil Sinha, and David B. Bharucha
- Subjects
medicine.medical_specialty ,Physical medicine and rehabilitation ,business.industry ,Physiology (medical) ,medicine ,Table (database) ,Head up tilt ,Cardiology and Cardiovascular Medicine ,business - Published
- 2005
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.